S&P 500   3,606.02 (-0.89%)
DOW   29,523.41 (-1.29%)
QQQ   296.24 (-0.93%)
AAPL   117.62 (+0.88%)
MSFT   211.18 (-1.88%)
FB   271.92 (-2.12%)
GOOGL   1,753.78 (-1.86%)
AMZN   3,142.12 (-1.67%)
TSLA   577.34 (-1.44%)
NVDA   523.45 (-1.32%)
BABA   264.96 (-4.17%)
CGC   28.40 (-2.07%)
GE   10.26 (-1.35%)
MU   64.11 (-0.19%)
AMD   89.44 (+2.58%)
T   28.87 (-0.55%)
NIO   51.28 (-5.04%)
F   9.11 (+0.22%)
ACB   10.72 (+2.39%)
NFLX   483.53 (-1.59%)
BA   210.82 (-2.62%)
GILD   59.73 (-0.50%)
DIS   146.92 (-0.14%)
S&P 500   3,606.02 (-0.89%)
DOW   29,523.41 (-1.29%)
QQQ   296.24 (-0.93%)
AAPL   117.62 (+0.88%)
MSFT   211.18 (-1.88%)
FB   271.92 (-2.12%)
GOOGL   1,753.78 (-1.86%)
AMZN   3,142.12 (-1.67%)
TSLA   577.34 (-1.44%)
NVDA   523.45 (-1.32%)
BABA   264.96 (-4.17%)
CGC   28.40 (-2.07%)
GE   10.26 (-1.35%)
MU   64.11 (-0.19%)
AMD   89.44 (+2.58%)
T   28.87 (-0.55%)
NIO   51.28 (-5.04%)
F   9.11 (+0.22%)
ACB   10.72 (+2.39%)
NFLX   483.53 (-1.59%)
BA   210.82 (-2.62%)
GILD   59.73 (-0.50%)
DIS   146.92 (-0.14%)
S&P 500   3,606.02 (-0.89%)
DOW   29,523.41 (-1.29%)
QQQ   296.24 (-0.93%)
AAPL   117.62 (+0.88%)
MSFT   211.18 (-1.88%)
FB   271.92 (-2.12%)
GOOGL   1,753.78 (-1.86%)
AMZN   3,142.12 (-1.67%)
TSLA   577.34 (-1.44%)
NVDA   523.45 (-1.32%)
BABA   264.96 (-4.17%)
CGC   28.40 (-2.07%)
GE   10.26 (-1.35%)
MU   64.11 (-0.19%)
AMD   89.44 (+2.58%)
T   28.87 (-0.55%)
NIO   51.28 (-5.04%)
F   9.11 (+0.22%)
ACB   10.72 (+2.39%)
NFLX   483.53 (-1.59%)
BA   210.82 (-2.62%)
GILD   59.73 (-0.50%)
DIS   146.92 (-0.14%)
S&P 500   3,606.02 (-0.89%)
DOW   29,523.41 (-1.29%)
QQQ   296.24 (-0.93%)
AAPL   117.62 (+0.88%)
MSFT   211.18 (-1.88%)
FB   271.92 (-2.12%)
GOOGL   1,753.78 (-1.86%)
AMZN   3,142.12 (-1.67%)
TSLA   577.34 (-1.44%)
NVDA   523.45 (-1.32%)
BABA   264.96 (-4.17%)
CGC   28.40 (-2.07%)
GE   10.26 (-1.35%)
MU   64.11 (-0.19%)
AMD   89.44 (+2.58%)
T   28.87 (-0.55%)
NIO   51.28 (-5.04%)
F   9.11 (+0.22%)
ACB   10.72 (+2.39%)
NFLX   483.53 (-1.59%)
BA   210.82 (-2.62%)
GILD   59.73 (-0.50%)
DIS   146.92 (-0.14%)
Log in
NYSE:QGEN

QIAGEN Stock Forecast, Price & News

$48.46
-0.03 (-0.06 %)
(As of 11/30/2020 11:33 AM ET)
Add
Compare
Today's Range
$48.42
Now: $48.46
$49.34
50-Day Range
$46.09
MA: $49.61
$54.74
52-Week Range
$30.23
Now: $48.46
$55.27
Volume7,860 shs
Average Volume1.65 million shs
Market Capitalization$11.04 billion
P/E Ratio1,615.33
Dividend YieldN/A
Beta0.31
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels (DNA and RNA), library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company has collaboration agreements with Amgen Inc., CLIA-certified laboratories, and NuProbe Global. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Read More
QIAGEN logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone31-77-355-6600
Employees5,300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.53 billion
Cash Flow$2.46 per share
Book Value$11.14 per share

Profitability

Net Income$-41,460,000.00

Miscellaneous

Market Cap$11.04 billion
Next Earnings Date2/2/2021 (Estimated)
OptionableOptionable
$48.46
-0.03 (-0.06 %)
(As of 11/30/2020 11:33 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











QIAGEN (NYSE:QGEN) Frequently Asked Questions

How has QIAGEN's stock price been impacted by Coronavirus?

QIAGEN's stock was trading at $41.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, QGEN shares have increased by 19.5% and is now trading at $49.11.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of QIAGEN?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for QIAGEN in the last year. There are currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for QIAGEN
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than QIAGEN?

Wall Street analysts have given QIAGEN a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but QIAGEN wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is QIAGEN's next earnings date?

QIAGEN is scheduled to release its next quarterly earnings announcement on Tuesday, February 2nd 2021.
View our earnings forecast for QIAGEN
.

How were QIAGEN's earnings last quarter?

QIAGEN (NYSE:QGEN) posted its quarterly earnings data on Tuesday, October, 27th. The company reported $0.58 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.56 by $0.02. The firm earned $483.76 million during the quarter, compared to analysts' expectations of $449.50 million. QIAGEN had a net margin of 0.86% and a return on equity of 15.85%.
View QIAGEN's earnings history
.

What guidance has QIAGEN issued on next quarter's earnings?

QIAGEN updated its fourth quarter 2020 IntraDay earnings guidance on Tuesday, October, 27th. The company provided EPS guidance of 0.58-0.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.66. The company issued revenue guidance of $512.70528-525.10944 million, compared to the consensus revenue estimate of $517.73 million.

What price target have analysts set for QGEN?

18 brokers have issued twelve-month price targets for QIAGEN's shares. Their forecasts range from $36.00 to $66.00. On average, they expect QIAGEN's stock price to reach $51.28 in the next year. This suggests a possible upside of 4.4% from the stock's current price.
View analysts' price targets for QIAGEN
.

Are investors shorting QIAGEN?

QIAGEN saw a increase in short interest in October. As of October 30th, there was short interest totaling 4,390,000 shares, an increase of 23.3% from the October 15th total of 3,560,000 shares. Based on an average trading volume of 1,170,000 shares, the short-interest ratio is presently 3.8 days. Currently, 2.0% of the company's shares are sold short.
View QIAGEN's Short Interest
.

Who are some of QIAGEN's key competitors?

What other stocks do shareholders of QIAGEN own?

Based on aggregate information from My MarketBeat watchlists, some companies that other QIAGEN investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).

Who are QIAGEN's key executives?

QIAGEN's management team includes the following people:
  • Mr. Thierry Bernard, Chief Exec. Officer (Age 55, Pay $1.21M)
  • Dr. Roland Sackers, CFO, MD & Member of Management Board (Age 51, Pay $925k)
  • Mr. Peer Michael Schatz, Sr. Advisor (Age 54, Pay $7.55M)
  • Dr. Barthold Piening, Sr. VP & Head of Global Operations (Age 62)
  • Mr. John Gilardi, VP of Corp. Communications & Investor Relations
  • Ms. Stephany Foster, SVP & Head of HR
  • Dr. Thomas Schweins, Sr. VP of Life Science Bus. Area
  • Dr. Thomas Theuringer, Sr. Director & Head of External Communications
  • Mr. Jean-Pascal Viola, SVP, Head of the Molecular Diagnostics Bus. Area and Co. Bus Dev Intellectual Propty & Litigation
  • Dr. Jonathan Sheldon, Sr. VP of Qiagen Digital Insights Bus. Area

What is QIAGEN's stock symbol?

QIAGEN trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Who are QIAGEN's major shareholders?

QIAGEN's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.01%), DekaBank Deutsche Girozentrale (1.21%), State Street Corp (0.92%), First Trust Advisors LP (0.67%), Swiss National Bank (0.40%) and Morgan Stanley (0.32%).

Which institutional investors are selling QIAGEN stock?

QGEN stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Caisse DE Depot ET Placement DU Quebec, Sycomore Asset Management, Ossiam, Arrowstreet Capital Limited Partnership, State Street Corp, UBS Asset Management Americas Inc., and First Trust Advisors LP.

Which institutional investors are buying QIAGEN stock?

QGEN stock was bought by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale, Acadian Asset Management LLC, Morgan Stanley, Grandeur Peak Global Advisors LLC, AQR Capital Management LLC, Origin Asset Management LLP, Exane Derivatives, and Exane Derivatives.

How do I buy shares of QIAGEN?

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is QIAGEN's stock price today?

One share of QGEN stock can currently be purchased for approximately $49.11.

How big of a company is QIAGEN?

QIAGEN has a market capitalization of $11.18 billion and generates $1.53 billion in revenue each year. The company earns $-41,460,000.00 in net income (profit) each year or $1.43 on an earnings per share basis. QIAGEN employs 5,300 workers across the globe.

What is QIAGEN's official website?

The official website for QIAGEN is www.qiagen.com.

How can I contact QIAGEN?

QIAGEN's mailing address is HULSTERWEG 82, VENLO P7, 5912. The company can be reached via phone at 31-77-355-6600 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.